<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900822</url>
  </required_header>
  <id_info>
    <org_study_id>CR 02/05</org_study_id>
    <nct_id>NCT00900822</nct_id>
  </id_info>
  <brief_title>Straumann Bone Ceramic Versus BioOss in Sinus Elevation</brief_title>
  <official_title>Randomized, Controlled Clinical Study to Compare Bone Formation Around Micro-implants in the Maxilla After Sinus Floor Augmentation With Straumann Bone Ceramic or Bio-Oss in a Split Mouth Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Straumann AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Straumann Bone Ceramic (SBC) and BioOss will be used as bone grafting materials when there is
      a need for bone augmentation in the posterior upper jaw. 9 months later the bone formation is
      evaluated. The patients are followed for 3 years.The study hypothesis is that the SBC is not
      worse than BioOss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Straumann Bone Ceramic (SBC) and BioOss will be used as bone grafting materials when there is
      a need for bone augmentation in the posterior upper jaw. The bone grafting materials will be
      placed into the sinus cavity,(a routine procedure), one material randomly at each side and a
      micro-implant will be inserted simultaneously. 9 months later the micro-implant is removed
      and a regular Straumann SLActive implant is inserted. The micro-implant is evaluated
      histologically. The site is evaluated every 12 months for 3 years in regards to clinical
      measurements. The study hypothesis is that the SBC is not worse than BioOss.

      Study design: Prospective, randomized, open, controlled, single center, split mouth

      Study population: 11 male and female patients at an age of between 18 and 80 years, affected
      by edentulism of both lateral-posterior maxilla and presenting two pneumatized maxillary
      sinuses and necessitating rehabilitation with implant-supported prostheses will be recruited
      in the study and treated by means of maxillary sinus floor augmentation and delayed implant
      placement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histologically Measured Bone to Implant Contact (BIC)</measure>
    <time_frame>9 months after implant placement</time_frame>
    <description>Results from morphometric measurements of percentage of new bone in contact with the total surface of the titanium implant, area of new bone and bone graft particles in contact with bone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant Survival Rate</measure>
    <time_frame>12 months after loading the implant</time_frame>
    <description>The percentage of implants remaining in the jaw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Success Rate</measure>
    <time_frame>12 months after loading the implant</time_frame>
    <description>Implant success is defined as the absence of any continuous peri-implant radiolucency based on radiographic findings, absence of implant mobility, absence of a recurrent per-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more 3-month follow-up visits after treatment with systemic antibiotics), and bone level changes around the implant less than 1 mm during the first year of loading and less than 0.2 mm per year thereafter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Jaw, Edentulous, Partially</condition>
  <condition>Alveolar Bone Loss</condition>
  <arm_group>
    <arm_group_label>Straumann Bone Ceramic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>StraumannBone Ceramic is used as bone grafting material in sinus augmentation procedures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioOss</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BioOss is used as a bone grafting material in sinus augmentation procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Straumann Bone Ceramic</intervention_name>
    <description>Granules applied once during surgery</description>
    <arm_group_label>Straumann Bone Ceramic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioOss</intervention_name>
    <description>Granules that are applied once during surgery</description>
    <arm_group_label>BioOss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 years to 80 years of age

          -  The patients are at least partly edentulous in the both maxillary regions
             corresponding to the sinuses.

          -  A dental implant procedure is foreseen in both maxilla regions corresponding to
             maxillary sinuses.

          -  Patients must be expected to present a bilateral bone defect in the sinus area, which
             both need a sinus floor augmentation to place one or more dental implants each.

          -  Residual alveolar crest height of the lateral-posterior segments of the edentulous
             maxilla below the floor of each of the maxillary sinuses shall be

          -  less than 5 mm and at least 2 mm, as measured by Scanora - tomography Scans in the
             deepest floor of the sinus

          -  residual alveolar crest width should be at least in average more than 4mm as measured
             by Scanora - tomography scans

          -  Patients must be committed to the study and must sign informed consent.

          -  Oral hygiene Index less than 25%

        Exclusion Criteria:

          -  Any systemic medical condition that could interfere with the surgical procedure or
             planned treatment

          -  Current pregnancy at the time of recruitment

          -  Physical handicaps that would interfere with the ability to perform adequate oral
             hygiene

          -  Alcoholism or chronically drug abuse causing systemic compromize

          -  Patients who smoke more than 10 cigarettes per day

          -  Medication which interferes with bone formation

          -  Conditions or circumstances, in the opinion of the investigator, which could represent
             a general contra-indication for surgical procedure or would prevent completion of
             study participation or interfere with analysis of study results, such as history of
             non-compliance, or unreliability

          -  Mucosal diseases such as erosive lichen planus

          -  History of local radiation therapy

          -  Presence of oral lesions (such as ulceration, malignancy)

          -  Severe bruxing or clenching habits

          -  Persistent intraoral infection

          -  Previous GBR (bone graft) or dental implant treatment in the posterior segments of the
             upper maxilla (foreseen implant site)

          -  Patients presenting clinical and radiological signs and symptoms of maxillary sinus
             disease

          -  Existing teeth in the residual dentition with untreated endodontic problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Hallman, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for oral maxillofacial surgery, Gävle hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Mats Hallman</name>
      <address>
        <city>Gävle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Lindgren C, Mordenfeld A, Hallman M. A prospective 1-year clinical and radiographic study of implants placed after maxillary sinus floor augmentation with synthetic biphasic calcium phosphate or deproteinized bovine bone. Clin Implant Dent Relat Res. 2012 Mar;14(1):41-50. doi: 10.1111/j.1708-8208.2010.00224.x. Epub 2010 May 11.</citation>
    <PMID>20491816</PMID>
  </results_reference>
  <results_reference>
    <citation>Lindgren C, Sennerby L, Mordenfeld A, Hallman M. Clinical histology of microimplants placed in two different biomaterials. Int J Oral Maxillofac Implants. 2009 Nov-Dec;24(6):1093-100.</citation>
    <PMID>20162114</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <results_first_submitted>June 6, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2012</results_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone grafting</keyword>
  <keyword>sinus elevation</keyword>
  <keyword>sinus augmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaw, Edentulous</mesh_term>
    <mesh_term>Alveolar Bone Loss</mesh_term>
    <mesh_term>Jaw, Edentulous, Partially</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started Oct 2005 and was completed June 2006.</recruitment_details>
      <pre_assignment_details>Split-mouth design (test and control in the same patient).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Straumann BoneCeramic</title>
          <description>Synthetic bone graft material</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>9 Months Histological Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>12 Months Clinical Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Straumann Bone Ceramic</title>
          <description>Synthetic bone graft material</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.27" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Implant Survival Rate</title>
        <description>The percentage of implants remaining in the jaw.</description>
        <time_frame>12 months after loading the implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Straumann Bone Ceramic</title>
            <description>Synthetic bone graft material</description>
          </group>
          <group group_id="O2">
            <title>BioOss</title>
            <description>Xenograft bone graft material</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival Rate</title>
          <description>The percentage of implants remaining in the jaw.</description>
          <units>percentage of implants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Histologically Measured Bone to Implant Contact (BIC)</title>
        <description>Results from morphometric measurements of percentage of new bone in contact with the total surface of the titanium implant, area of new bone and bone graft particles in contact with bone</description>
        <time_frame>9 months after implant placement</time_frame>
        <population>This was a split-mouth design. Each patient received both treatments. There was one sample in the Straumann BoneCeramic group that could not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Straumann BoneCeramic</title>
            <description>Synthetic bone graft material</description>
          </group>
          <group group_id="O2">
            <title>BioOss</title>
            <description>Xenograft bone graft material</description>
          </group>
        </group_list>
        <measure>
          <title>Histologically Measured Bone to Implant Contact (BIC)</title>
          <description>Results from morphometric measurements of percentage of new bone in contact with the total surface of the titanium implant, area of new bone and bone graft particles in contact with bone</description>
          <population>This was a split-mouth design. Each patient received both treatments. There was one sample in the Straumann BoneCeramic group that could not be analyzed.</population>
          <units>percentage of total surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.552" spread="9.036"/>
                    <measurement group_id="O2" value="54.904" spread="15.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Success Rate</title>
        <description>Implant success is defined as the absence of any continuous peri-implant radiolucency based on radiographic findings, absence of implant mobility, absence of a recurrent per-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more 3-month follow-up visits after treatment with systemic antibiotics), and bone level changes around the implant less than 1 mm during the first year of loading and less than 0.2 mm per year thereafter.</description>
        <time_frame>12 months after loading the implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Straumann Bone Ceramic</title>
            <description>Synthetic bone graft material</description>
          </group>
          <group group_id="O2">
            <title>BioOss</title>
            <description>Xenograft bone graft material</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Success Rate</title>
          <description>Implant success is defined as the absence of any continuous peri-implant radiolucency based on radiographic findings, absence of implant mobility, absence of a recurrent per-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more 3-month follow-up visits after treatment with systemic antibiotics), and bone level changes around the implant less than 1 mm during the first year of loading and less than 0.2 mm per year thereafter.</description>
          <units>percentage of implants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6"/>
                    <measurement group_id="O2" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Straumann Bone Ceramic</title>
          <description>Synthetic bone graft material</description>
        </group>
        <group group_id="E2">
          <title>BioOss</title>
          <description>Xenograft bone graft material</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Exposure of implant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Implant infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mobile implant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fenestration of implant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Contact between cover screw and prosthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinial Trial Manager</name_or_title>
      <organization>Institut Straumann AG</organization>
      <phone>+41 61 965 11 11</phone>
      <email>info@straumann.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

